Mozambique vs Myanmar: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Mozambique
70.0%
in 2025
Myanmar
71.0%
in 2025
Mozambique rank
132nd
Myanmar rank
131st
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Mozambique
- Myanmar
How they compare
Myanmar currently reports 71.0% against 70.0% in Mozambique, a difference of 1.0%.
The two have swapped places 6 times across 18 shared years of data; in 2008 it was Myanmar ahead.
Mozambique ranks 132nd and Myanmar ranks 131st of 192 countries.
Mozambique has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Mozambique | Myanmar | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 52.1% | 28.4% | 23.7% | Mozambique |
| 2020s | 64.8% | 64.8% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Mozambique or Myanmar?
- Myanmar, at 71.0% against 70.0% in Mozambique as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Mozambique and Myanmar?
- 1.0%, with Myanmar ahead.
- How many years of comparable data are there for Mozambique and Myanmar?
- 18 years are reported by both, from 2008 to 2025.
- How do Mozambique and Myanmar rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Mozambique ranks 132nd and Myanmar ranks 131st of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.